BGE-102 Data Inspires Confidence for BioAge Labs (BIOA)

BioAge Labs Inc. (NASDAQ:BIOA) is one of the 7 best small-cap drug manufacturing stocks to buy according to hedge funds.

On March 10, Citi maintained a Buy rating on BioAge Labs Inc. (NASDAQ:BIOA). The firm significantly increased its price target from $15 to $52, citing a compelling outlook as the company approaches proof-of-concept data for BGE-102.

Tonhom1009/Shutterstock.com

Citi also sees significant commercial potential for the therapy across multiple indications, including peak U.S. sales of $9.5B for atherosclerotic cardiovascular disease and $2B for diabetic macular edema, supporting a more optimistic view of the company’s long-term growth trajectory.

On February 25, Oppenheimer began coverage of BioAge Labs Inc. (NASDAQ:BIOA) with a $60 price target and an Outperform rating. The firm is quite positive about the company’s lead compound, BGE-102, which can inhibit the NLRP3 pathway. This has recently received a lot of attention due to the potential of the compound in the reduction of cardiovascular risk, especially after the positive Phase 2 results from Ventyx Biosciences.

Oppenheimer points out the critical differentiation of the company’s compound in comparison to other adjacent NLRP3 and Interleukin compounds.

BioAge Labs Inc. (NASDAQ:BIOA) is engaged in developing therapeutic product candidates for metabolic diseases. Its product portfolio includes an NLRP3 inhibitor in Phase 1 of clinical trial and BGE-102. It is also working on APJ agonists for obesity.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.